Abstract

S. A. Khan*, Mohammad Imran, M. F. Arshad and Suresh Kumar

Selective COX-2 inhibitors were believed to reduce the side effect profile of classical NSAIDs. Recent pharmacological studies have indicated certain controversies regarding the safety of selective COX-2 inhibitors as another important arachidonic acid pathway, 5-LOX pathway, is upregulated during COX inhibition. To combat these controversies a new strategy, dual inhibition of COX-2 and 5-LOX has been developed. This strategy constitutes a valuable alternative to classical NSAIDs and selective COX-2 inhibitors for the treatment of inflammatory diseases. This review article highlights the therapeutic interest of designing dual COX-2/5-LOX inhibitors along with the various chemical families of dual inhibitors.

Pyridazinone; Anticonvulsant activity

[ View HTML Full Text]